Chimeric Therapeutics Ltd. is a clinical stage cell therapy company, which engages in the development and commercialization of cell therapies in oncology. Its products include NK Cell Derived Allogenic Therapies and T Cell Derived Autologous Therapies. The company was founded by Paul A. Hopper in 2020 and is headquartered in Carlton South, Australia.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Chimeric Therapeutics Limited?
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Chimeric Therapeutics Limited market cap is $44,900.00.
What is the 52-week high for Chimeric Therapeutics Limited?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Chimeric Therapeutics Limited 52 week high is $0.10 as of May 16, 2026.
What is the 52-week low for Chimeric Therapeutics Limited?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Chimeric Therapeutics Limited 52 week low is $0.001 as of May 16, 2026.
What is Chimeric Therapeutics Limited stock price today?
Chimeric Therapeutics Limited stock price today is $0.10.
What was Chimeric Therapeutics Limited stock price yesterday?
Chimeric Therapeutics Limited stock price yesterday was $3.00.
What is the Price-to-Book ratio of Chimeric Therapeutics Limited?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Chimeric Therapeutics Limited P/B ratio is -0.0203.
What is the 50-day moving average of Chimeric Therapeutics Limited?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Chimeric Therapeutics Limited 50-day moving average is $0.0683.